Alpha-Defensin Levels Are Elevated in Patients With Myositis-Related Lung Disease | Research

The takeaway

Patients with myositis-associated interstitial lung disease had significantly higher alpha-defensin levels in their blood and lung fluid compared to healthy controls, suggesting these antimicrobial peptides may reflect disease activity.

Significantly elevated HNP levels in both plasma and lung fluid
Alpha-defensin levels in myositis-ILD patients were higher than healthy controls and correlated with neutrophil counts and CT scan abnormalities

What the researchers found

Alpha-defensin (HNP 1-3) levels were significantly elevated in both plasma and bronchoalveolar lavage fluid (BALF) of myositis-associated ILD patients compared to healthy controls. Plasma HNP levels correlated with total cell counts in BALF. BALF HNP levels positively correlated with serum surfactant protein-A and the percentage of neutrophils in lung fluid.

In patients positive for anti-aminoacyl-tRNA synthetase (anti-ARS) antibodies, BALF HNP levels also correlated with the percentage of reticular opacities on high-resolution CT scans. However, survival did not differ between patients with higher and lower HNP levels.

Why it matters

Myositis-associated ILD is a serious condition with limited prognostic tools. If alpha-defensins can serve as biomarkers for disease activity, they could help doctors monitor lung involvement and guide treatment decisions. This also supports the broader concept that neutrophil-derived antimicrobial peptides play roles beyond infection control — they participate in autoimmune inflammation.

How the study worked

This was a case-control study comparing 56 patients with myositis-associated ILD to 24 healthy controls. HNP (alpha-defensin 1-3) levels were measured in plasma and bronchoalveolar lavage fluid using ELISA. Results were correlated with other disease markers including serum surfactant protein-A, BALF cell counts, and high-resolution CT findings.

What this study cannot tell us

The sample size was relatively small (56 patients). Survival was not significantly different between high and low HNP groups, limiting the prognostic value. The study is observational and cannot determine whether elevated defensins cause lung damage or are simply a marker of neutrophilic inflammation. Further studies are needed to confirm clinical utility.

How to read the evidence

This is an observational case-control study with a modest sample size. It identifies a correlation between defensin levels and disease activity but does not establish causation or clinical utility as a validated biomarker.

When this study was published

Published in 2018, this study reflects current understanding of defensin biology in autoimmune lung disease. The biomarker findings would need validation in larger cohorts for clinical adoption.

The bigger picture

Alpha-defensins are increasingly recognized as more than just antimicrobial agents — they're active players in inflammation and immune regulation. This study adds to evidence that defensin levels may serve as biomarkers in autoimmune and inflammatory lung diseases, potentially offering a new way to track disease activity in conditions where monitoring is difficult.

Questions still open

Could alpha-defensin levels be used clinically to guide treatment intensity in myositis-associated ILD?
Do elevated defensins actively contribute to lung tissue damage in autoimmune conditions, or are they purely a marker of neutrophil activation?
Would anti-defensin therapies have any role in reducing lung inflammation in myositis patients?

Common questions

What are alpha-defensins and why are they in the lungs?

Alpha-defensins are small antimicrobial peptides stored inside neutrophils, a type of white blood cell. When neutrophils are activated by inflammation or infection, they release defensins. In myositis-associated lung disease, neutrophils flood the lung tissue and release large amounts of defensins, which is why levels are elevated.

Could measuring defensin levels help doctors treat myositis lung disease?

Potentially. If defensin levels reliably track how active the lung disease is, doctors could use them to decide when to intensify or reduce treatment. However, this study is preliminary — larger studies are needed before defensin testing could be used in routine clinical practice.

Read the original research

Elevated α-defensin levels in plasma and bronchoalveolar lavage fluid from patients with myositis-associated interstitial lung disease.

BMC pulmonary medicine, 18(1), 44

View on PubMed ↗Publisher’s paper ↗

Citation

Sakamoto, Noriho; Ishimoto, Hiroshi; Kakugawa, Tomoyuki; Satoh, Minoru; Hasegawa, Tomoko; Tanaka, Shin; Hara, Atsuko; Nakashima, Shota; Yura, Hirokazu; Miyamura, Takuto; Koyama, Hanako; Morita, Towako; Nakamichi, Seiko; Obase, Yasushi; Ishimatsu, Yuji; Mukae, Hiroshi. (2018). Elevated α-defensin levels in plasma and bronchoalveolar lavage fluid from patients with myositis-associated interstitial lung disease.. BMC pulmonary medicine, 18(1), 44. https://doi.org/10.1186/s12890-018-0609-5